Mirapex ER (Pramipexole Di-HCl) Patent Expiration, LOE Window & CMS Spending

Mirapex ER (Pramipexole Di-HCl) by Boehringer Ingelheim: FDA Orange Book LOE 2029-09-08, 9 AB generics, $54K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBoehringer Ingelheim
FDA Application & PathwayN022514 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2029-09-08
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors9
2024 CMS Total Public Spend$54K
2024 Medicare Part D Spend$54K
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.